Baxter Healthcare Sa

Bia Separations D.o.o.

Avir Green Hills Biotechnology Research Development Trade Ag

Elisabeth Roethl

Thomas Muster

Markus Wolschek

Andrej Egorov

Ales Strancar

Julia Romanova

Michael Bergmann

Matjaz Peterka

Petra Kramberger

Marko Banjac

A process for the purification of influenza virus or derivative thereof requires providing a source of influenza virus or derivative thereof, optionally subjecting the source to a pre-purification step, followed by subjecting the source to at least one chromatographic step on chromatographic material selected from the group consisting of porous particles having mean pore sizes of at least 20 nm, perfusion particles, gel-in-a-shell particles, tentacle like particles, membrane adsorbers, and monoliths, and collecting fractions eluted from the chromatographic material that contain the influenza virus or derivative thereof, excluding sulfuric ester of cellulose or cross-linked polysaccharides.

Method for influenza virus purification

The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.

High growth reassortant influenza A virus

Growing community of inventors

Vienna, Austria

Elisabeth Roethl